Dr. Reddy’s Laboratories has announced the approval of stock options for eligible employees under its Employees Stock Option Schemes. The Nomination, Governance and Compensation Committee of the Board of Directors approved the grant at a meeting held on 11 May 2026.
The company has granted a total of 8,16,119 Indian Stock Options under the Dr. Reddy’s Employees Stock Option Scheme, 2018. Additionally, 3,76,115 American Depository Receipts (ADRs) Stock Options have been granted under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007. Both grants are intended for eligible employees of the company.
Each stock option, whether Indian or ADR, is priced at a fair market value of ₹1,293.90 per share. The vesting schedule for these options indicates 100% vesting at the end of three years, after which the options may be exercised according to the respective vesting schedule.
The stock options are governed and administered by the Nomination, Governance and Compensation Committee. The schemes comply with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
These grants are part of Dr. Reddy’s ongoing efforts to incentivise and retain talent within the company by aligning employee interests with those of the shareholders.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).